I don't think that is why the stock is selling off. The data is as good as one could have realistically expected. This is just the way it goes with biotech investing. I didn't hear any complaints from the board when many of these same filthy animals ran it up to $13.50. It's part of the deal, like it or not.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.